How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?

Expert Opinion on Biological Therapy

Volumn 14, Issue 6, 2014, Pages 743-748

  Bronte, Giuseppe ^a   Rolfo, Christian ^b   Peeters, Marc ^b   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Algorithm; Chemotherapy; Metastatic colorectal cancer; Salvage treatment; Target therapy

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB; ANTINEOPLASTIC AGENT;

BIOLOGICAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; HUMAN; LIVER METASTASIS; LUNG METASTASIS; METASTATIC COLORECTAL CANCER; ONCOLOGIST; REVIEW; SALVAGE THERAPY; SYSTEMIC THERAPY; TREATMENT PLANNING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ALGORITHM; CLINICAL PATHWAY; COLORECTAL TUMOR; LIVER NEOPLASMS; LIVER RESECTION; LUNG NEOPLASMS; LUNG RESECTION; METASTASIS RESECTION; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATIENT SELECTION; PROCEDURES; SECONDARY; TREATMENT OUTCOME;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CRITICAL PATHWAYS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; METASTASECTOMY; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; PATIENT SELECTION; PNEUMONECTOMY; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84900826629     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.902926     Document Type: Review

References (21)

1. Quan D, Gallinger S, Nhan C, et al. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery 2012;151(6):860-70
2. Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum-applying current evidence to clinical practice. Cancer Treat Rev 2012;38(5):397-406
3. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23(10):2479-516
4. Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012;30(15):1755-62
5. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377(9783):2103-14
6. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229-37
7. Rizzo S, Bronte G, Fanale D, et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 2010;36(Suppl 3):S56-61
8. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29(15):2011-19
9. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34
10. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-19
11. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37
12. Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol 2012;23(9):2313-18
13. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44
14. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506
15. Tabernero J, Van Cutsem E, Lakomý R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014;50(2):320-31
16. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):303-12
17. Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010;28(19):3191-8
18. Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14(11):1077-85
19. Loupakis F, Cremolini C, Masi G, et al. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): results of the phase III randomized TRIBE trial. 2013 Gastrointestinal Cancers Symposium; 2013. J Clin Oncol 2013;30(Suppl 34):abstract 336
20. Heinemann V, von Weikersthal LF, Decker T, et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). 2013 ASCO Annual Meeting; Chicago; 2013. J Clin Oncol 2013;31(Suppl):abstract LBA3506
21. Rolfo C, Russo A, Santini D, et al. Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting. Expert Opin Ther Targets 2013;17(8):869-71